viewOptiBiotix Health PLC

OptiBiotix buoyed by UK launch of SlimBiome Medical

The weight loss product will be available to buy from Opti's website in boxes of 30 single-dose sachets from 29 April

Weight loss
Opti also reported prelaunch sales to Bridge4 Health, a health and well-being centre, for a three-month field trial to support weight loss among its gym members

OptiBiotix Health PLC (LON:OPTI) shares were buoyed on Wednesday after it launched its SlimBiome Medical weight management product in the UK market.

The company, which develops compounds to help tackle obesity, high cholesterol and diabetes, said SlimBiome would be available to buy from its website in boxes of 30 single-dose sachets from 29 April.

READ: OptiBiotix Health gets licence to manufacture weight management product SlimBiome in India

Opti also reported prelaunch sales to Bridge4 Health Ltd, a health and well-being centre based in Leicester, which would conduct a three-month field trial of the product to support weight loss among its gym members.

Fred Narbel, managing director of Opti’s Prebiotics division, said the UK launch would allow the group to “build early revenues at high margin through direct consumer sales”.

The launch follows SlimBiome receiving a CE mark in November last year, which allows it to be freely marketed within the European Economic Area (EEA).

READ: OptiBiotix surges as SlimBiome granted CE mark and medical device status

Since receiving the mark, the company has signed a slew of distribution deals for countries including Italy, Spain, Greece, Cyprus and Bulgaria.

More recently, the group has expanded its international presence, receiving a licence from the Food Standards and Safety Authority India earlier in April to manufacture SlimBiome in the country.

In mid-morning trading, OptiBiotix shares were up 1.7% at 82.9p.

 -- Adds share price --

Quick facts: OptiBiotix Health PLC

Price: 65.5 GBX

Market: AIM
Market Cap: £55.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...



Full interview: European healthcare broker sets 97p price target for...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara speaks to Proactive London following a research note whcih has been published on the company by Goetz partners - which has set OPTI a price target of 97p. O'Hara says Goetz partners are a leading European Investment Bank and broking firm and...

on 11/9/19

2 min read